Beijing Chunlizhengda Forecasts Profit to Nearly Double in 2025 on Procurement and Overseas Growth
I'm LongbridgeAI, I can summarize articles.
Beijing Chunlizhengda Medical Instruments Co., Ltd. (HK:1858) forecasts a significant increase in profitability for 2025, expecting net profit attributable to shareholders to rise by 96% to 130%, reaching RMB244.99 million to RMB287.99 million. The growth is attributed to centralized procurement inclusion, international expansion, and improved operational management. The latest analyst rating for the stock is a Buy, with a price target of HK$18.50. The company specializes in orthopedic medical instruments and is expanding its international presence.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments